Biomaterials - Bone substitutes - Spine fusion
SMART BIOMATERIALS
Graftys was born in September 2005, from a common desire to promote French Academic
Research within a proactive and dynamic structure.
Graftys has defined its strategic and commercial objectives in
view of establishing itself as an important actor on the biomaterials and biotechnology market.
By carefully nurturing company spirit, ensuring team expertise and pursuing
innovation, the company is doing everything to fulfil this ambition.
Our company, based in Aix-en-Provence, is already at the core of a network
of partners reaching far beyond our frontiers.
Our Research & Development activities range from latest generation synthetic bone substitutes to biological repair of cartilage and intervertebral discs, via resorbable bioactive cements and intelligent biomaterials (biomatériaux intelligents®).
Certified ISO 9001:2000 and ISO 13485:2003 , Graftys is committed to ensure the excellence of its products and services, thus guaranteeing total client satisfaction.
10/12/09 - GRAFTYS announces launch of QUICKSET
Graftys is pleased to announce that it is launching a second injectible and macroporous bone graft substitute: GRAFTYS QUICKSET (CE marked, FDA agreement submitted). This new formulation shares many key features with GRAFTYS HBS, which was launched early 2009 in the USA. In addition to its user-friendly closed mixing/injection system, both are injectible and macroporous, leading to an optimal resorption of the implant and replacement with natural healthy bone, and both offer incremental mechanical resistance capability. QUICKSET provides a shorter working time, added mechanical resistance, and thus expands the list of clinical indications for Graftys bone void fillers in orthopedic and dental applications. Graftys HBS & Graftys Quickset cover a very wide range of surgical requirements.
>> More Informations...
01/06/10 - Graftys to exhibit at AAOS 2010
Graftys will exhibit its products at the AAOS meeting, which will take place in New Orleans from 9-13 March, 2010. Please visit us at exhibit #4068 !
>> More Informations...
10/22/02 - GRAFTYS initiates clinical trial
GRAFTYS has initiated a clinical study designed to
demonstrate the effectiveness of a local treatment to prevent osteoporotic fractures.
Evaluation of this prospective, comparative, blinded study will involve safety and
efficacy of a minimally invasive femoroplasty using an injectable and resorbable
bisphosphonateloaded
synthetic bone substitute to prevent contralateral hip fracture after
osteoporotic fracture. The lead investigator is Professor J.N. Argenson, University
Hospital Sainte Marguerite, Marseille, France.
>> More Informations...
Biomaterials - Bone substitutes - Spine fusion
GRAFTYS - Eiffel Park - Bâtiment D - 415, rue Claude Nicolas Ledoux
Pôle d'Activités d'Aix en Provence - 13 854 AIX EN PROVENCE Cedex 3
Tel : + 33 (0)4 42 60 30 00 - Fax : + 33 (0)4 42 60 30 11